PD-L1 Blockade Differentially Impacts Regulatory T Cells from HIV-Infected Individuals Depending on Plasma Viremia

PLoS Pathogens

Volumn 11, Issue 12, 2015, Pages

  Peligero, Cristina ^a   Argilaguet, Jordi ^a   Güerri Fernandez, Roberto ^b   Torres, Berta ^c   Ligero, Carmen ^c   Colomer, Pilar ^b   Plana, Montserrat ^d   Knobel, Hernando ^b   García, Felipe ^c   Meyerhans, Andreas ^a,e  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD39 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAG PROTEIN; PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIMIT OF DETECTION; REGULATORY T LYMPHOCYTE; VIREMIA; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; VIROLOGY;

ANTIGENS, CD274; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HIV INFECTIONS; HUMANS; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES, REGULATORY; VIREMIA;

EID: 84953248299     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005270     Document Type: Article

References (53)

1. Pauken KE, Wherry EJ, Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015;36: 265–276. doi: 10.1016/j.it.2015.02.008 25797516
2. Nguyen LT, Ohashi PS, Clinical blockade of PD1 and LAG3—potential mechanisms of action. Nat Rev Immunol. 2015;15: 45–56. doi: 10.1038/nri3790 25534622
3. Velu V, Shetty RD, Larsson M, Shankar EM, Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options. Retrovirology. 2015;12: 14. doi: 10.1186/s12977-015-0144-x 25756928
4. Harvey RD, Immunologic and Clinical Effects of Targeting PD-1 in Lung Cancer. Clin Pharmacol Ther. 2014;96: 214–223. doi: 10.1038/clpt.2014.74 24690569
5. Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T, A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol. 2013;14: 1212–8. doi: 10.1038/ni.2762 24240160
6. Wherry EJ, T cell exhaustion. Nat Immunol. 2011;12: 492–499. 21739672
7. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439: 682–7. 16382236
8. Velu V, Titanji K, Zhu B, Husain S, Pladevega A, Lai L, et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature. 2009;458: 206–210. doi: 10.1038/nature07662 19078956
9. Shetty RD, Velu V, Titanji K, Bosinger SE, Freeman GJ, Silvestri G, et al. PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques. J Clin Invest. 2012;122: 1712–16. doi: 10.1172/JCI60612 22523065
10. Fuller MJ, Callendret B, Zhu B, Freeman GJ, Hasselschwert DL, Satterfield W, et al. Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). PROC NATL ACAD SCI U S A. 2013;110: 15001–6. doi: 10.1073/pnas.1312772110 23980172
11. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006;443: 350–354. 16921384
12. Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B, et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med. 2006;12: 1198–1202. 16917489
13. Porichis F, Kwon DS, Zupkosky J, Tighe DP, McMullen A, Brockman MA, et al. Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. Blood. 2011;118: 965–974. doi: 10.1182/blood-2010-12-328070 21652684
14. Souza MD, Fontenot AP, Mack DG, Lozupone C, Dillon S, Meditz A, et al. Programmed death 1 expression on HIV-specific CD4+T cells is driven by viral replication and associated with T cell dysfunction. J Immunol. 2007;179: 1979–1987. 17641065
15. Palmer BE, Neff CP, LeCureux J, Ehler A, DSouza M, Remling-Mulder L, et al. In vivo blockade of the PD-1 receptor suppresses HIV-1 viral loads and improves CD4+ T cell levels in humanized mice. J Immunol. 2013;190: 211–219. doi: 10.4049/jimmunol.1201108 23209326
16. Seung E, Dudek TE, Allen TM, Freeman GJ, Luster AD, Tager AM, PD-1 blockade in chronically HIV-1-infected humanized mice suppresses viral loads. PLoS One. 2013;8: e77780. doi: 10.1371/journal.pone.0077780 24204962
17. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA, Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272: 1167–1170. 8638160
18. Porichis F, Kaufmann DE, Role of PD-1 in HIV pathogenesis and as target for therapy. Curr HIV/AIDS Rep. 2012;9: 81–90. doi: 10.1007/s11904-011-0106-4 22198819
19. McGary CS, Silvestri G, Paiardini M, Animal models for viral infection and cell exhaustion. Curr Opin HIV AIDS. 2014;9: 492–9. doi: 10.1097/COH.0000000000000093 25023622
20. Keir ME, Butte MJ, Freeman GJ, Sharpe AH, PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26: 677–704. doi: 10.1146/annurev.immunol.26.021607.090331 18173375
21. Wing K, Sakaguchi S, Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol. 2010;11: 7–13. doi: 10.1038/ni.1818 20016504
22. Belkaid Y, Tarbell K, Regulatory T cells in the control of host-microorganism interactions. Annu Rev Immunol. 2009; 27:551–89 doi: 10.1146/annurev.immunol.021908.132723 19302048
23. Moreno-Fernandez ME, Presicce P, Chougnet CA, Homeostasis and Function of Regulatory Cells in HIV/SIV Infection. J Virol. 2012;86: 10262–10269. doi: 10.1128/JVI.00993-12 22811537
24. Chevalier MF, Weiss L, The split personality of regulatory T cells in HIV infection. Blood. 2013;121: 29–37. doi: 10.1182/blood-2012-07-409755 23043072
25. Seddiki N, Brezar V, Draenert R, Cell exhaustion in HIV-1 infection: role of suppressor cells. Curr Opin HIV AIDS. 2014;9: 452–458. doi: 10.1097/COH.0000000000000087 25010895
26. Krupnick AS, Gelman AE, Barchet W, Richardson S, Kreisel FH, Turka LA, et al. Murine vascular endothelium activates and induces the generation of allogeneic CD4+25+Foxp3+ regulatory T cells. J Immunol. 2005;175: 6265–6270. 16272276
27. Wang L, Pino-Lagos K, de Vries VC, Guleria I, Sayegh MH, Noelle RJ, Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. PROC NATL ACAD SCI U S A. 2008;105: 9331–9336. doi: 10.1073/pnas.0710441105 18599457
28. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009;206: 3015–29. doi: 10.1084/jem.20090847 20008522
29. Baecher-Allan C, Brown A. J, Freeman GJ, Hafler DA, CD4+CD25+regulatory cells from human peripheral blood express very high levels of CD25 ex vivo. Novartis Found Symp. 2003;252:67–88. 14609213
30. Zhou Q, Munger ME, Highfill SL, Tolar J, Weigel BJ, Riddle M, et al. Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood. 2010;116: 2484–93. doi: 10.1182/blood-2010-03-275446 20570856
31. Gotot J, Gottschalk C, Leopold S, Knolle P a, Yagita H, Kurts C, et al. Regulatory T cells use programmed death 1 ligands to directly suppress autoreactive B cells in vivo. PROC NATL ACAD SCI U S A. 2012;109: 10468–73. doi: 10.1073/pnas.1201131109 22689978
32. Wong M, La Cava A, Hahn BH, Blockade of programmed death-1 in young (New Zealand Black x New Zealand White)F1 mice promotes the suppressive capacity of CD4+ regulatory T cells protecting from lupus-like disease. J Immunol. 2013;190: 5402–5410. doi: 10.4049/jimmunol.1202382 23636058
33. Park HJ, Park JS, Jeong YH, Son J, Ban YH, Lee BH, et al. PD-1 upregulated on regulatory T cells during chronic virus infection enhances the suppression of CD8+ T cell immune response via the interaction with PD-L1 expressed on CD8+ T Cells. J Immunol. 2015;194: 5801–11. doi: 10.4049/jimmunol.1401936 25934860
34. Franceschini D, Paroli M, Francavilla V, Videtta M, Morrone S, Labbadia G, et al. PD-L1 negatively regulates CD4+CD25+FOXP3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J Clin Invest. 2009;119: 551–564. doi: 10.1172/JCI36604 19229109
35. Joedicke JJ, Dietze KK, Zelinskyy G, Dittmer U, The phenotype and activation status of regulatory T cells during Friend retrovirus infection. Virol Sin. 2014;29: 48–60. doi: 10.1007/s12250-014-3396-z 24452537
36. Lim A, French MA, Price P, CD4 + and CD8 + T cells expressing FoxP3 in HIV-infected patients are phenotypically distinct and influenced by disease severity and antiretroviral therapy. J Acquir Immune Defic Syndr. 2009;51: 248–257. doi: 10.1097/QAI.0b013e3181a74fad 19363449
37. Rueda CM, Velilla PA, Chougnet CA, Rugeles MT, Incomplete normalization of regulatory T-cell frequency in the gut mucosa of Colombian HIV-infected patients receiving long-term antiretroviral treatment. PLoS One. 2013;8: e71062. doi: 10.1371/journal.pone.0071062 23967152
38. Cho H, Kikuchi M, Li Y, Nakamoto N, Amorosa VK, Valiga ME, et al. Induction of multiple immune regulatory pathways with differential impact in HCV/HIV coinfection. Front Immunol. 2014;5: 256.
39. Kim PS, Ahmed R, Features of responding T cells in cancer and chronic infection. Curr Opin Immunol. 2010;22: 223–230. doi: 10.1016/j.coi.2010.02.005 20207527
40. Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, et al. Functional delineation and differentiation dynamics of human CD4+T cells expressing the FoxP3 transcription factor. Immunity. 2009;30: 899–911. doi: 10.1016/j.immuni.2009.03.019 19464196
41. Simonetta F, Bourgeois C, CD4+FOXP3+ regulatory T-cell subsets in human immunodeficiency virus infection. Front Immunol. 2013;4: 215. doi: 10.3389/fimmu.2013.00215 23908654
42. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996;8: 765–772. 8671665
43. Meier A, Bagchi A, Sidhu HK, Alter G, Suscovich TJ, Kavanagh G, et al. Up-regulation of PD-L1 on monocytes and dendritic cells by HIV-1 derived TLR ligands. AIDS. 2008;22: 655–658. doi: 10.1097/QAD.0b013e3282f4de23 18317010
44. Boasso A, Hardy AW, Landay AL, Martinson JL, Anderson SA, Dolan MJ, et al. PD-L1 upregulation on monocytes and T cells by HIV via type I interferon: restricted expression of type I interferon receptor by CCR5-expressing leukocytes. Clin Immunol. 2008;129: 132–144. doi: 10.1016/j.clim.2008.05.009 18650129
45. Rodríguez-García M, Porichis F, de Jong OG, Levi K, Diefenbach TJ, Lifson JD, et al. Expression of PD-L1 and PD-L2 on human macrophages is up-regulated by HIV-1 and differentially modulated by IL-10. J Leukoc Biol. 2011;89: 507–515. doi: 10.1189/jlb.0610327 21097698
46. Bowers NL, Helton ES, Huijbregts RPH, Goepfert P a., Heath SL, Hel Z, Immune suppression by neutrophils in HIV-1 infection: Role of PD-L1/PD-1 pathway. PLoS Pathog. 2014;10: e1003993. doi: 10.1371/journal.ppat.1003993 24626392
47. Zhang JY, Zhang Z, Wang X, Fu JL, Yao J, Jiao Y, et al. PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors. Blood. 2007;109: 4671–4678. 17272504
48. Penaloza-MacMaster P, Kamphorst AO, Wieland A, Araki K, Iyer SS, West EE, et al. Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. J Exp Med. 2014;211: 1905–1918. doi: 10.1084/jem.20132577 25113973
49. Dietze KK, Zelinskyy G, Liu J, Kretzmer F, Schimmer S, Dittmer U, Combining regulatory T cell depletion and inhibitory receptor blockade improves reactivation of exhausted virus-specific CD8+ T ells and efficiently reduces chronic retroviral loads. PLoS Pathog. 2013;9: e1003798. doi: 10.1371/journal.ppat.1003798 24339778
50. Akbar AN, Vukmanovic-stejic M, Taams LS, Macallan DC, The dynamic co-evolution of memory and regulatory CD4 + T cells in the periphery. Nat Rev Immunol. 2007;7: 231–237. 17318234
51. Vukmanovic-Stejic M, Agius E, Booth N, Dunne PJ, Lacy KE, Reed JR, et al. The kinetics of CD4+ Foxp3+ T cell accumulation during a human cutaneous antigen-specific memory response in vivo. J Clin Invest. 2008;118: 3639–3650. doi: 10.1172/JCI35834 18924611
52. Barnaba V, Schinzari V, Induction, control, and plasticity of Treg cells: The immune regulatory network revised? Eur J Immunol. 2013;43: 318–22. doi: 10.1002/eji.201243265 23408318
53. Carter L, Fouser LA, Jussif J, Fitz L, Deng B, Wood CR, et al. PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2. Eur J Immunol. 2002;32: 634–643. 11857337